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Investing in global mental health: the time for action is now
Despite widespread acknowledgement of the 
economic and global burden of mental disorders 
(as represented in years of life lost to disability and 
mortality), acting on these concerns and creating an 
investment plan for global mental health has been 
challenging.1,2 This failure can be explained by many 
factors, including scepticism about prevalence data 
for mental disorders. Without precise biological 
measures, these disorders might be viewed as being 
defined culturally by high-income countries, or as 
having overly inclusive criteria that reject traditional 
ideas of normal human suffering. Additionally, a 
perceived absence of effective treatments in low-
income countries already facing overwhelming 
challenges of infectious diseases and other disorders 
and limited infrastructure might make attention 
to mental illnesses less of an immediate priority. 
Likewise, mental disorders might be more overtly 
associated with disability than death, despite evidence 
of early mortality due to suicide or other medical 
disorders.3
Furthermore, mental illnesses are highly stigma-
tised. Sitting at the boundary of behaviour, neuro-
biology, and culture, they remain—irrespective of 
cause—the most intimate and personal of medical 
disorders, and challenge expectations for self-
control and more traditional views of human nature. 
Irrespective of these challenges, through persistent 
advocacy, mental health has for the first time 
been formally incorporated in the United Nations 
Sustainable Development Goals for 2016–30.4 
However, concerns about the effectiveness or 
feasibility of investment in mental health disorders 
might be continuing to impede needed wide scale 
interventions. Mental disorders receive a very small 
proportion of national health expenditures or external 
development support. In view of these problems, 
the study by Dan Chisholm and colleagues5 is very 
important.
Chisholm and colleagues have, for the ﬁ rst time, 
modelled using the WHO OneHealth tool the 
investment needed to bring care of depression and 
anxiety disorders worldwide to minimally acceptable 
levels. They estimated the investment cost for 80% 
of the world’s population at US$141 billion between 
2016 and 2030, using the WHO Mental Health Gap 
Action Programme (mhGAP) intervention guide, which 
assumes the use of non-specialist physicians, nurses, 
and community health workers.6 They further analysed 
the return on investment using two endpoints: 
economic beneﬁ t (ie, enhanced productivity) and 
the imputed value of the years of improved health. 
Although the conﬁ dence intervals around this analysis 
were substantial and were dependent on the model’s 
assumptions, they estimated that the beneﬁ t to 
cost ratio of the investment was 2·3–3·0 when only 
workforce issues were considered. That number 
increased to 3·5–5·7 when the implicit value of years of 
health gained were included.
Although this number is less than that recorded in 
many interventions, it is important to note that other 
potential eﬀ ects of interventions were not considered. 
These include the eﬀ ect of treated depression and 
anxiety on maternal-child health, or the eﬀ ect on other 
general health disorders that are more prevalent and 
costly in people with mental disorders. The Chisholm 
study brings rigour to the economic case, but there are 
many other important reasons to consider enhanced 
investment in global mental health, not least of which 
are justice, equity, human rights, and the reduction of 
suﬀ ering.
So what should be done to support more widespread 
investment by governments and non-governmental 
organisations including foundations in advancing the Mik
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global mental health infrastructure? First, there needs 
to be a recognition that even using a conservative 
estimate of the burden of mental disorders, their 
contribution to medical care costs, disability, lost life, 
and lost productivity is substantial. Indeed, in view 
of their high prevalence and early life onset, failure 
to address mental health will impede general health 
goals and risk other social and economic development. 
Second, although extensive data exist for the eﬃ  cacy 
of both psychotherapeutic and psychopharmacological 
interventions for many psychiatric disorders, more 
extensive demonstration projects in countries with 
highly limited medical infrastructures are needed.7 
Third, working with international agencies such as 
WHO, there needs to be an updated roadmap for 
investment that accounts for changes in disease 
burden over time. Fourth, because psychiatric 
disorders are highly stigmatised, the will to invest in 
care will require a parallel international campaign to 
destigmatise these disorders and, most importantly, 
will need to be understood as an eﬀ ort to secure 
fundamental and inalienable human rights to care and 
treatment.
Finally, to achieve a sustained effect on global 
mental health, major international organisations, 
governments, and foundations will need to be 
engaged. The publication of this report is therefore 
timely, coinciding with the first-ever joint meeting 
of the World Bank and WHO on the global economic 
effect of depression and anxiety on April 13–14, 
2016. This is a very important initial step, but only a 
predicate to overdue and much needed bold action. 
There are many examples of the effect of such 
leadership, including in mental health. In the 1930s 
the Rockefeller Foundation invested heavily in the 
scientific transformation of academic psychiatry, 
neurology, and their related care systems in the USA, 
the UK, and elsewhere.8,9 Their leadership signalled 
an understanding that because infectious diseases in 
these countries were increasingly effectively treated, 
non-communicable and chronic diseases would 
replace them as major disease burdens. Of these, 
psychiatric illnesses represented the largest unmet 
clinical and scientific need. These investments set the 
stage for the post-World War 2 scientific and clinical 
development of psychiatry. That so many of the 
Rockefeller leadership also had personal experience 
with mental illnesses made this a profoundly cour-
ageous and visionary act.9
The time has come for a similar global investment 
in mental health, understanding, as the Rockefeller 
leadership did, that as infectious, water borne, and 
child health illness outcomes improve, the relative 
burden of non-communicable diseases will increase 
and that mental disorders will be among the most 
important.10 We will neither achieve our health or 
development goals if we fail to move towards those 
who are suﬀ ering, and we will violate the core tenets 
of our common humanity if we fail to help those who 
are ill take their rightful place among the citizens of the 
world. The time for open hearted and generous action 
is now.
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